West Nile virus pre-membrane and envelope proteins (WNV prM/E)

The West Nile virus (WNV) pre-membrane and envelope (prM/E) proteins are the primary structural components forming the outer shell of the virion [1.1.3, 1.2.2]. The envelope (E) protein is the major surface glycoprotein responsible for host cell receptor binding and pH-dependent membrane fusion, while the pre-membrane (prM) protein acts as a chaperone to ensure proper E protein folding and prevent premature fusion during viral egress [1.2.1, 1.2.5]. These antigens are the principal targets for neutralizing antibodies, which primarily recognize domain III of the E protein to block viral entry [1.5.2, 1.5.4]. In the context of disease, WNV is a neurotropic flavivirus that can cause West Nile fever and severe neuroinvasive conditions such as encephalitis and meningitis [1.3.2, 1.5.2]. Therapeutic development focuses on vaccines, such as ChimeriVax-WN02 and various DNA or viral vector platforms, and monoclonal antibodies like MGAWN1, which aim to elicit or provide protective immunity [1.3.1, 1.4.3, 1.5.4]. A critical challenge in targeting these antigens is the risk of antibody-dependent enhancement (ADE), where cross-reactive antibodies may facilitate the infection of related flaviviruses like Dengue or Zika [1.3.2, 1.3.3]. Despite several candidates reaching clinical trials, no human vaccine or specific antiviral therapy is currently approved [1.3.2, 1.4.4].

Other names

West Nile virus prM/E antigensWNV structural proteins prM and EWest Nile virus envelope and pre-membrane proteinsWNV surface glycoproteinsWNV prM and E proteins

Vaccines and monoclonal antibodies targeting these antigens work by inducing or providing neutralizing antibodies that bind to the envelope (E) protein, particularly domain III, to block viral attachment to host cell receptors and prevent membrane fusion, thereby inhibiting viral entry and infection [1.5.2, 1.5.4].